[1] |
XIONG Weiyi, REN Jingtian.
Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
|
[2] |
LIU Saiyue, LYU Xiaoqin, ZHOU Yun.
Key points of investigation and report of suspected death of adverse drug reaction
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
|
[3] |
CHU Yanqi, JIANG Yongxian, SHEN Jianghua, XING Xiaoxuan, ZHANG Qingxia, YAN Suying.
Analgesia-related risks after thoracoscopic surgery in elderly patients
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1023-1026.
|
[4] |
XIAO Wangzhong, LIN Cong, HUANG Li, DAI Bing, GAO Yuanfeng.
Contraindications in package inserts of Chinese patent medicine
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 400-403.
|
[5] |
LUO Yichong, CAI Liping, PU Yanfang, ZHAO Jinhua.
Routes of Administration Described in Specifications of 236 Types of Intravenous Injections
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 872-875.
|
[6] |
JU Shan, LIU Yinghui, WANG Yawen, TENG Yingying, JIANG Yan, DENG Gang, SUN Lei.
Clinical Evaluation of Medical Devices Seen from International Coordination Documents
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1062-1065.
|
[7] |
WANG Jiayu, YU Dandan, LI Ming, WANG Ling, LIU Pengcheng, SUN Jun.
Current Abuse/Use of Compound Tramadol in Drug Abusers
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 98-105.
|
[8] |
ZHAO Shuang, SONG Yanqing, WANG Xiangfeng, JINFang, MIAO Qiuli.
Analysis of Pediatric Use Information in Package Inserts of Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(9): 555-560.
|
[9] |
LIU Huan, ZHANG Zhongyi, YANG Yue.
Safety Report Management in New Drug Clinical Trials
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(2): 88-93.
|
[10] |
HONG Wei, WANG Feng.
Current Construction of Monitoring and Evaluation System of Adverse Drug Reactions in Anhui Province
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 722-726.
|
[11] |
WANG Dan, LI Xinling, DONG Duo, XIONG Weiyi, LIU Cuili, ZHU Lan, GENG Fengying, LIAO Jianbo, YANG Yueming, LAN Shan, LV Xiaoqin, WANG Tongchun, ZHAO Xia, WANG Wen.
Investigation of Pharmaceutical Manufacturers’ Ability of Direct Reporting of Drug Adverse Reactions
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 654-661.
|
[12] |
WANGYan-li.
Investigation and Analysis of 40 Groups of Injection Drugs in Our Hospital
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(3): 147-151.
|
[13] |
LI Ang, ZHANG Bing.
Survey and Consideration on Safety Status of Traditional Chinese Medicine Application in 685 Primary Healthcare Workers
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(12): 721-727.
|
[14] |
ZHAO Xia, LENG Meiling, WANG Peng, LI Xinling, CAO Lujuan, TIAN Chunhua, LIU Cuili.
Research on Current Status and Countermeasures of Information Collection on Adverse Drug Reactions by Drug Manufacturers from Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 652-657.
|
[15] |
LI Ang, ZHANG Bing, ZHANG Xiao-meng, SUN Xiao-xia, YANG Xue, LI Fan.
Investigation on the Situation of Cognition and Reporting of Adverse Drug Reactions in 1 109 Basic Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 289-294.
|